Clinical Trials Browser

Toll-Like Receptor 1 × Clear all

NCT07406724 2026-02-12

HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma

Phase 2 Not yet recruiting

Melanoma

NCT01701674 2025-12-19

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Phase NA Completed

13 enrolled 10 charts

Melanoma, Skin Neoplasms

NCT04614103 2025-11-12

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Phase 2 Recruiting

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT06088472 2025-09-29

TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Solid Tumors, Adult

NCT03108495 2025-09-17

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

Phase 2 Terminated

Uterine Cervical Neoplasms

NCT03645928 2025-06-19

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Phase 2 Recruiting

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05576077 2025-03-10

STARLING

Phase 1 Terminated

BreastDermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT04111510 2024-11-21

Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

Phase 2 Completed

6 enrolled 13 charts

Triple Negative Breast Neoplasms

NCT03083873 2023-10-12

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Phase 2 Completed

64 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck

NCT03374839 2022-05-06

Nivo-TIL

Phase 1/2 Unknown

Melanoma

NCT03419559 2019-04-16

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT00200577 2017-06-01

TIL

Phase 3 Completed

Melanoma